減損損失 - 医薬品、負債の部合計、連結子会社の決算期の変更に伴う増減他1件
- 【期間】
| 年度 | 減損損失 - 医薬品 | 負債の部合計 | 連結子会社の決算期の変更に伴う増減 | 投資有価証券評価損 |
|---|
| 2008/03 | - | | 1.35兆 | | - | | - | |
| 2009/03 | - | | 1.25兆 | -7.8% | - | | 41.4億 | |
| 2010/03 | - | | 1.56兆 | +25.3% | - | | - | |
| 2011/03 | - | | 1.61兆 | +2.9% | - | | - | |
| 2012/03 | - | | 1.62兆 | +0.5% | -154百万 | | - | |
| 2013/03 | 4.3億 | | 1.72兆 | +6.7% | 665百万 | 黒転 | 47.1億 | +13.7% |
| 2014/03 | 70.9億 | 大幅増 | 1.85兆 | +7.5% | - | | 14.6億 | -68.9% |
| 2015/03 | 53.1億 | -25.1% | 1.76兆 | -5% | - | | - | |
| 2016/03 | 5.53億 | -89.6% | 1.57兆 | -10.8% | - | | - | |
| 2017/03 | - | | 1.7兆 | +8.2% | - | | - | |
| 2018/03 | - | | 1.14兆 | -32.8% | - | | - | |
| 2019/03 | - | | 1.15兆 | +0.3% | - | | - | |
| 2020/03 | - | | 1.26兆 | +10.1% | - | | - | |
| 2021/03 | - | | 1.38兆 | +9.7% | - | | 31.1億 | +112.8% |
| 2022/03 | - | | 1.37兆 | -0.9% | - | | 25億 | -19.7% |
| 2023/03 | - | | 1.39兆 | +1.7% | - | | 43.9億 | +75.7% |
| 2024/03 | - | | - | | - | | - | |
